Sales in hemophilia A will remain higher despite inferior extension to factor VIII half-lives.
By Hardik Patel, Lead Analyst
30 March 2016
I am Lead Analyst for oncology at Datamonitor Healthcare, based in the New York office. I have a Bachelor of Science deg...
Read full bio
Across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), Datamonitor Healthcare estimates that there were approximately 3 million prevalent cases of chemotherapy-induced anemia (CIA) in bladder, breast, colorectal, gastric, head and neck, non-small cell lung, ovarian, and uterine cancer in 2015. While Datamonitor Healthcare predicts that the number of prevalent cases of CIA will rise due to population growth and aging, as well as increasing cancer incidence and survival, future changes in cancer treatment will also affect the prevalent population of CIA; however, the impact of changes to cancer treatment on the prevalence of CIA remains to be seen.
Datamonitor Healthcare estimates that the majority of prevalent cases had grade 1 (mild) anemia, while just under a third of cases had grade 2 (moderate) anemia, and less than 10% had either grade 3 (severe) or 4 (very severe) anemia. Datamonitor Healthcare found that the severity of CIA differed by cancer type. This trend is likely a consequence of differences in the type of chemotherapeutic agents used to treat each cancer. Specifically, platinum-based chemotherapeutics, which have greater myelosuppressive effects than other chemotherapy drugs, are less frequently used to treat breast or colorectal cancer compared to lung and gynecological cancers, for example. Other factors likely to affect the severity of CIA include cancer stage, chemotherapy treatment duration and intensity, and patient characteristics such as age and the presence of co-morbidities.
Severity of prevalent cases of chemotherapy-induced anemia in the US, Japan, and five major EU markets, by anemia grade and cancer type, 2015
Source: Datamonitor Healthcare
Datamonitor Healthcare’s Hemophilia: Forecast explores the impact of long-acting recombinant concentrate factor therapies on the hemophilia A and B markets, in addition to outlining the sales outlook of key drugs used in each disease.
Get your free demo today – simply fill out the form to the right.